ライフサイエンスコーパス: antibody response

1 tures required for a protective neutralizing antibody response.

2 at VlsE was likely the primary target of the antibody response.

3 quirement for CD4 T cells in the anti-glycan antibody response.

4 of viraemia and the absence of an anamnestic antibody response.

5 , and are often targeted by the neutralizing antibody response.

6 le viral loads and the lack of an anamnestic antibody response.

7 influences the magnitude and quality of the antibody response.

8 duced a broader, heterosubtypic neutralizing antibody response.

9 ses and recapitulated the serum neutralizing antibody response.

10 dies provide only a narrow view of the total antibody response.

11 xis and suggest that a second dose may boost antibody responses.

12 B cell antigen receptor (BCR), and thus for antibody responses.

13 nd low-titer tier 1B and tier 2 neutralizing antibody responses.

14 to partially overcome strain-specific immune antibody responses.

15 vaccine has proven to be potent in eliciting antibody responses.

16 ease agents that have evolved to avoid human antibody responses.

17 4 T cell differentiation as well as impaired antibody responses.

18 s vaccines primarily elicit species-specific antibody responses.

19 iated responses and provide optimal help for antibody responses.

20 nce, as well as high-titer and Fc-functional antibody responses.

21 ulations in the generation of vaccine-evoked antibody responses.

22 ructure is essential to achieve neutralizing antibody responses.

23 e quality of immunization-induced polyclonal antibody responses.

24 gies to enhance systemic and mucosal SIV/HIV antibody responses.

25 d to characterize all IgG subclasses and IgE antibody responses.

26 n-gamma producing T cells correlated with H5 antibody responses.

27 d identify potential molecular correlates of antibody responses.

28 ith E2 being the main target of neutralizing antibody responses.

29 n boys increasing age appears to improve the antibody responses.

30 cated as a negative regulator of IgE and IgG antibody responses.

31 neration of class-switched, antigen-specific antibody responses.

32 lls in uninfected mice led to suppression of antibody responses.

33 pealing target for priming broadly effective antibody responses.

34 elicited robust GM2-specific overall and IgG antibody responses.

35 pathogen and is a useful model for studying antibody responses.

36 Ebola vaccine candidate elicited anti-Ebola antibody responses.

37 on immune cells, are important regulators of antibody responses.

38 ls, as a key physiological target to control antibody responses.

39 sm by which infection induces suppression of antibody responses.

40 ractor (TACI) is important for T-independent antibody responses.

41 tion was well tolerated and generated robust antibody responses.

42 neages and determine the predominant mode of antibody responses.

43 This includes detailed antibody responses after 23-valent pneumococcal polysacc

44 Then, we compared antibody responses after infection of humans with influe

45 with a malarial antigen efficiently induced antibody responses after only a single immunization.

46 ion with ART led to a progressive decline in antibody responses after treatment induction that persis

47 is the primary target of human neutralizing antibody response against hepatitis C virus (HCV), and i

48 reanalyzed proteome microarray data of host antibody response against Plasmodium falciparum.

49 IV infection, a relatively weak neutralizing antibody response against primary and subtype-specific n

50 This reduction was associated with an antibody response against the human albumin-based carrie

51 Protection correlated with an antibody response against the NEAT domains and a decreas

52 a heterologous IAV, despite improving their antibody responses against a secondary IAV infection.

53 avalent vaccine elicited potent neutralizing antibody responses against all four DENV serotypes.

54 e was well tolerated and elicited functional antibody responses against all vaccine serotypes.

55 correlated with immune cell infiltration and antibody responses against DFTD cells.

56 nstrating a need to measure epitope-specific antibody responses against each DENV serotype.

57 imer immunogens elicited potent neutralizing antibody responses against highly sensitive Tier 1A isol

58 L adjuvants in promoting robust and durable antibody responses against HIV in the next generation of

59 X313 is a very promising strategy to enhance antibody responses against Pfs25, and that Pfs25-IMX313

60 djuvants in promoting high-titer, long-lived antibody responses against Pfs25.

61 juvant in inducing persistent and protective antibody responses against SIV in RMs with implications

62 RM197 produced high-titer IgG and opsonizing antibody responses against the CPS component of the glyc

63 Current vaccines focus on eliciting specific antibody responses against the hemagglutinin (HA) surfac

64 e found to have defective B1 B-cell-mediated antibody responses against the T-cell-independent antige

65 Furthermore, mild to moderate antibody responses against the TTSuV1 ORF2 protein was d

66 es formulated with Advax(CpG) induced robust antibody responses against various forms of both, Abeta

67 10 years) cannot be ascertained by measured antibody responses alone.

68 o mothers with history of wild-type measles, antibody responses among children born to vaccinated mot

69 for many years, however cross-reactivity of antibody responses among the flaviviruses has been a con

70 motifs in the immunogen to elicit a broader antibody response and enhance protection.

71 ationship between the intensity of the human antibody response and entomological indicators of transm

72 64U1 elicited an earlier increase of binding antibody responses and altered the specificity of the Ig

73 ells and are associated both with protective antibody responses and autoimmune diseases.

74 be further developed to enhance neutralizing antibody responses and boost CD8 T cells to provide robu

75 al influenza A virus infection by modulating antibody responses and decreasing the numbers and activi

76 pox-prime/protein boost regimen can augment antibody responses and enhance protection from a SHIV ch

77 strating the significance of epitopes in HLA antibody responses and matching for organ transplantatio

78 ut diverse roles in early and late phases of antibody responses and plasma cell differentiation.

79 rISFV vaccine vectors elicited neutralizing antibody responses and protected mice from lethal VEEV a

80 er infant protection and the risk of reduced antibody responses and secondary vaccine failure among s

81 ce diversity, we measured EBV gp350-specific antibody responses and sequenced the gp350 gene in sampl

82 The neutralizing antibody responses and the epitopes targeted against DEN

83 useful for investigation of domain-specific antibody responses and the more extensive definition of

84 it is now known that autologous neutralizing antibody responses and their selection of neutralization

85 parasites develop within host cells to avoid antibody responses and to utilize host cytoplasmic resou

86 summarized how mismatched eplet loads affect antibody responses and transplant outcomes.

87 uced H3-specific hemagglutination inhibition antibody responses, and consequently might affect vaccin

88 In contrast, ARR-induced lower antibody responses, and protection was associated with p

89 V-C F&G induced both AMPV-C and NDV-specific antibody responses, and provided significant protection

90 eedle-free injection had detectable positive antibody responses, and the geometric mean titre of 304

91 Antibody responses are essential for protection against

92 Such analyses of site-specific antibody responses are imperative to our assessment of t

93 The current study explored whether antibody responses are noninferior after 2 versus 3 dose

94 e recognized by these potentially protective antibody responses are only poorly defined.

95 We investigated whether HIV antibody responses as measured by high-throughput quanti

96 red to demonstrate noninferiority of the VZV antibody response at 6 weeks in the booster-dose group,

97 ine were well tolerated and induced a robust antibody response at antigen-sparing doses in healthy ad

98 dose based on analysis of serotype-specific antibody responses at delivery (+72 h) for use in subseq

99 immunoglobulin (Ig) G, IgA, and neutralizing antibody responses at week 2 were all significantly high

100 n delays the development of antigen-specific antibody responses but does not permanently impair their

101 NV infections develop long-term neutralizing antibody responses, but these principally recognize only

102 We measured antibody responses by ELISA of an extensive panel of rec

103 CD47-SIRPalpha interaction improve antitumor antibody responses by enhancing antibody-dependent cellu

104 Thus, mTOR drives innate-like antibody responses by linking proximal TACI signaling ev

105 lts in long-term antibody nonresponsiveness, antibody responses can be induced by adenovirus vector i

106 nical studies indicate that antigen-specific antibody responses can be maintained for many years, lea

107 While the quantity of vaccine-induced antibody responses can be measured in a viral neutraliza

108 ate that endogenous polyclonal anti-cytokine antibody responses can enhance the cytokine's activity i

109 As markers of exposure anti-malaria antibody responses can help characterise heterogeneity i

110 ther investigation.IMPORTANCE Elicitation of antibody responses capable of neutralizing diverse HIV-1

111 rotein vaccine induced robust neutralization antibody responses comparable to those generated by live

112 safe and effective and induces an increased antibody response compared with standard influenza vacci

113 ded DMN patches induced significantly higher antibody responses compared to intramuscular-based immun

114 rhesus macaques elicited a rapid and robust antibody response, conferring complete protection upon c

115 llel, to characterize the serum neutralizing antibody responses, convalescence-phase serum samples fr

116 B-cell reconstitution resulted in a primary antibody response, demonstrating that MZ B-cell depletio

117 Protective high-affinity antibody responses depend on competitive selection of B

118 unknown function, fails to evoke detectable antibody responses despite its extracellular exposure.

119 By 1 month, an antibody response developed in 70.8% of the participants

120 tokine and adaptive (T cell and neutralising antibody) responses disproportionate to their replicatio

121 Progestins reduced the antibody responses during primary H1N1 virus infection b

122 CHIKV vaccine is available, and whether the antibody response elicited by one genotype can neutraliz

123 20 protein or MVA-expressed gp140 to enhance antibody responses elicited by the GOVX-B11 DNA prime-MV

124 her and sustainable levels of virus-specific antibody responses, especially IgA levels and hemaggluti

125 However, antibody responses established after natural RSV infecti

126 T cell responses but had minimal effects on antibody responses except for suppressing serum IgA resp

127 The duration of antibody response following reduced human papillomavirus

128 drifted viruses; however, generally limited antibody response following vaccination is concerning ev

129 ociated with the development of neutralizing antibody responses following AIM.

130 ertoire is impaired and antigen-specific IgG antibody responses following immunization are blunted in

131 nvelope (Env) and characterizing the primary antibody response for HIV-1 neutralization.

132 ed hypoallergenic variant showing protective antibody response for immunotherapeutic applications.

133 e-control study in which CMV-specific plasma antibody responses from 19 CMV-transmitting and 57 CMV-n

134 Although antibody responses generated to one variant were potentl

135 In addition to their role in protection, antibody responses have been hypothesized to contribute

136 t, with T cell responses as well as detailed antibody responses having been characterized.

137 Systems serology of the antibody responses identifies plasma antibody binding to

138 s time also induced a dominant gp41-reactive antibody response.IMPORTANCE Our results are critical to

139 In the present work, we investigated the antibody response in a cohort of chronically infected in

140 ated the in vitro and in vivo properties and antibody response in ferrets to 20 diverse H10 viruses.

141 nfounded by the complexity of the polyclonal antibody response in humans.

142 To examine the antibody response in individuals who develop high titers

143 To determine whether the robust antibody response in infants is due to differences in va

144 Indeed, rRABV-mBAFF induced a faster, higher antibody response in mice and enhanced survivorship in P

145 The prM-E VLPs induced a strong neutralizing antibody response in mice that was better when the capsi

146 ed if the DNA/rAd5 vaccine induced a similar antibody response in rhesus macaques (RMs), which are co

147 We aimed to compare the post-booster antibody response in UK infants given a reduced priming

148 MMR induces similar antibody responses in 12-month-old children as compared

149 djuvants differently modulate gp120-specific antibody responses in adults and infants and that infant

150 rapid elicitation of broad and potent serum antibody responses in all four cows.

151 Here we demonstrate that induction of antibody responses in C57BL/6 mice can occur at a time d

152 We compared the antibody responses in girls previously vaccinated with z

153 PreF vaccine elicited rapid RSV neutralizing antibody responses in healthy young men, with an accepta

154 ontrast to SUDV survivors, rare neutralizing antibody responses in MARV survivors diminished rapidly

155 013 elicited potent and durable neutralizing antibody responses in mice and non-human primates.

156 Exaggerated antibody responses in mice depleted of CD301b(+) DCs occ

157 Spls elicited IgE antibody responses in most asthmatic patients.

158 transcripts is consistent with the anti-MAP antibody responses in paratuberculosis sheep.

159 At 12 months, antibody responses in participants in the ChAd3-EBO-Z gr

160 V vaccine that elicited broadly neutralizing antibody responses in preclinical trials.

161 nonhuman primates revealed the importance of antibody responses in preventing HIV-1 infection.

162 nts to a role for polyclonal vaccine-induced antibody responses in protection from infection.

163 d the elicitation of potent isolate-specific antibody responses in rabbits and macaques, but so far f

164 and that they induced conformation-specific antibody responses in rabbits.

165 rRABV-mBAFF induced similar anti-RABV antibody responses in SAP-deficient and wild-type mice,

166 e vaccine elicited strong virus neutralizing antibody responses in sheep and was DIVA (differentiatin

167 ay allow the parasite to escape neutralizing antibody responses in some regions.

168 VLP) induces potent and durable Env-specific antibody responses in the serum and in vaginal secretion

169 le target to modulate human T cell dependent antibody responses in the settings of infection, vaccina

170 Previously, we profiled the antibody responses in type A and B tularemia cases in th

171 Dominant antibody responses in vaccinees who received the HIV-1 m

172 signatures that correlate with Env-specific antibody responses in vaginal secretions and protection

173 r prolonged Ct infection had a less focussed antibody response, including preferential recognition of

174 avage feeding with PN, they mounted specific antibody responses, including PN-specific IgE.

175 fective in patients with an increased B-cell/antibody response indicated by high autoantibody titers.

176 ted significant immunoglobulin (Ig)G and IgM antibody responses, indicating bacterial colonization/in

177 We demonstrate that the improved early antibody responses induced by rRABV-mBAFF confer improve

178 e variant were potently inhibiting IL-1beta, antibody responses induced by the other variant even pot

179 The neutralization antibody responses induced by the VLPs were significantl

180 d CCL28 induces significantly higher mucosal antibody responses, involved in providing long-term cros

181 Strong antibody response is considered a hallmark of a successf

182 igens and to which the dominant neutralizing antibody response is directed during natural infection.

183 iduals and found that a broadly neutralizing antibody response is protective and is associated with r

184 Our results also show that consideration of antibody responses is required in cases where rapamycin

185 ve of not significantly boosting the mucosal antibody response, it augmented the frequency of IFN-gam

186 Nanopatch delivery elicits faster antibody response kinetics, with high titres of neutrali

187 tion-resistant viruses may induce irrelevant antibody responses less frequently than do other Envs an

188 The earliest IgG antibody response, mainly directed against S1 polypeptid

189 s and on how functional heterogeneity of the antibody response may explain a century of contradictory

190 On the other hand, antibody responses may be sustained solely by short-live

191 Our data suggest that maternal neutralizing antibody responses may play a role in protection against

192 outcomes were tolerability and GBS-specific antibody response (measured as geometric mean concentrat

193 n appears responsible for the suppression of antibody responses observed in infected mice because PTE

194 Tregs also were able to suppress the recall antibody response of murine splenocytes from FVIII knock

195 Novel immunogens were designed to focus the antibody response of rabbits on the V1V2 epitopes of HIV

196 ed robust innate responses, antigen-specific antibody responses of a greater magnitude and persistenc

197 nse and reactivity with long-term persistent antibody responses of acquired natural immunity.

198 ly discovered OPXV, Akhmeta virus, exhibited antibody responses of greater intensity and broader reco

199 o 6 years following first administration and antibody responses over 5 years.

200 uction of long-lasting primary and secondary antibody responses post-RABV immunization.IMPORTANCE Ext

201 and how these T cells directly contribute to antibody response remains unclear.

202 rains enable the evasion of virus-inhibiting antibody responses, resulting in vaccine failure.

203 Assessment of the durability of the antibody response showed that titers remained high at we

204 Protective antibody responses, such as those against oxidized lipid

205 hin bacteria has a more marked effect on the antibody response than on the CD4(+) T cell response, wh

206 more potent secondary anti-RABV neutralizing antibody response than rLBNSE-immunized mice.

207 MNP boost could better maintain the humoral antibody response than that by the conventional vaccine-

208 f autologous versus V3-directed neutralizing antibody responses than the SOSIP-stabilized form.

209 n large quantities, has yet to induce better antibody responses than those to other envelope-based im

210 nes showed significantly better neutralizing antibody responses than those with their DNA counterpart

211 le for defects in B lymphocyte migration and antibody responses that accompany acute viral infection.

212 A vaccine candidate, PorB induces antibody responses that are directed against six variabl

213 D8 is also a target for neutralizing antibody responses that are elicited by the smallpox vac

214 tations are more likely to elicit protective antibody responses that are not affected by glycosylatio

215 haride-CRM197 constructs produced high-titer antibody responses that crossreacted with Bm-like OAgs.

216 These findings demonstrate that antibody responses that have been correlated with protec

217 LR ligands (NP) to induce potent and durable antibody responses that last a lifetime in mice.

218 sponse could elicit polyclonal anti-IL-1beta antibody responses that modulated IL-1beta's in vivo act

219 ediction is correct, it is expected that the antibody response to B. burgdorferi invariant antigens w

220 f microarrays for high-resolution mapping of antibody response to determine the nature of OPXV exposu

221 isease, but the characteristics of the human antibody response to EBOV GP remain poorly understood.

222 ar antigen, followed by a more rapid rise in antibody response to EBV antigens in children from the h

223 onsidered a major target of the neutralizing antibody response to hRSV.

224 Antibody response to P. falciparum was determined in 4,1

225 ked immunoassay platform to characterize the antibody response to PEDV whole-virus (WV) particles and

226 Antibody response to related flaviviruses has long been

227 ial first influenza A virus infection on the antibody response to subsequent vaccination.

228 l T-cell development and function and intact antibody response to T-dependent antigen.

229 By evaluating the cross-reactive antibody response to the H10 viruses and combining this

230 dition, in contrast to RTS,S, only a minimal antibody response to the HBsAg carrier was induced.

231 uma-induced corneas; however, a neutralizing antibody response to the vector capsid was observed inco

232 There was no difference in body condition, antibody response to vaccination, triiodothyronine (T3),

233 We also explored age-related HI antibody responses to 2012-2013 H3N2v viruses.

234 mptive pulmonary tuberculosis to measure IgG antibody responses to 57 M. tuberculosis antigens using

235 dengue should elicit long-lasting protective antibody responses to all four serotypes simultaneously.

236 ent study was to investigate the genetics of antibody responses to an acellular pertussis vaccine by

237 Hemagglutination inhibition (HAI) antibody responses to anti-influenza virus hyperimmune i

238 High rates of binding antibody responses to CRF01_AE antigens, including gp70

239 Antibody responses to DENV-positive C cases differ from

240 strate the power of exploring human anti-CSP antibody responses to develop tools for malaria control

241 ffective vaccination strategy to broaden the antibody responses to emerging viruses.

242 with our designed immunogens produced robust antibody responses to epitope I, and their serum could n

243 rrored by relationships between rhinitis and antibody responses to grass.

244 vaccination induced modest cross-reactive HI antibody responses to H5Nx viruses.

245 stration group and the noninferiority of the antibody responses to HZ/su and IIV4 in the coadministra

246 alone can significantly alter the quality of antibody responses to improve vaccine efficacy.

247 imary objective of this study was to compare antibody responses to intradermal vaccination in partici

248 bone marrow-derived plasma cells and durable antibody responses to multiple virus and vaccine antigen

249 Insight into age-related antibody responses to newly emerging H3N2v viruses is cr

250 microarray to characterize and differentiate antibody responses to nonvaccinia OPXV infections from s

251 In the present study antibody responses to Plasmodium falciparum AMA-1, MSP-1

252 ant role in regulation of allograft-specific antibody responses to prevent organ rejection in transpl

253 o were older when first immunized had higher antibody responses to priming doses for 18 of 21 antigen

254 eexisting maternal antibody inhibited infant antibody responses to priming doses for 20 of 21 antigen

255 Differences in the antibody responses to specific PEDV structural proteins

256 We sought to evaluate whether antibody responses to specific treponemal antigens measu

257 pre-activated lymphocyte subset that mounts antibody responses to T-cell-independent antigens throug

258 ly, individuals harbouring high and specific antibody responses to Tbg antigens but negative parasito

259 ty criteria were met for 3 antigens, and the antibody responses to the fourth antigen, influenza B/Br

260 ies that render the elicitation of effective antibody responses to the functional Env entry unit extr

261 Antibody responses to the inactivated seasonal influenza

262 tibody profiling of the mucosal and systemic antibody responses to the nearly complete V. cholerae O1

263 lade 2.3.4) vaccine to elicit cross-reactive antibody responses to these emerging viruses.

264 ructure-based design of immunogens to induce antibody responses to this epitope.

265 e find autoimmune mice generate neutralizing antibody responses to tier 2 HIV-1 strains with alum tre

266 on-inducing ligand-driven B-cell activation, antibody responses to TNP-Ficoll, production of natural

267 previous exposure to influenza virus shapes antibody responses to vaccination and infection is criti

268 ings demonstrate an augmented macrophage and antibody response toward xenografts compared with allogr

269 Alum-TLR7 also drives antibody response towards Th1 isotypes.

270 e glycoprotein of dengue virus dominated the antibody response, two smaller groups of antibodies boun

271 humans and elicited autologous neutralizing antibody responses typical of HIV-1.

272 Vaccinia virus is a powerful model to study antibody responses upon vaccination, since its use as th

273 The pneumococcal polysaccharide antibody response was impaired in 87% of patients (ie, a

274 s, viral replication, and the cross-reactive antibody response, we identified A/mallard/Portugal/7990

275 To assess the breadth and magnitude of antibody responses, we sequentially infected mice, guine

276 Serum antibody responses were assessed by competitive Luminex

277 The resulting polyclonal anti-IL-1beta antibody responses were assessed by using in vitro and i

278 Serum HAI antibody responses were detected in 0 of 32 younger subj

279 PfSPZ-specific T-cell and antibody responses were detected in all vaccine recipien

280 Vaccine antigen-specific serum antibody responses were detected in both the intramuscul

281 Cholera-specific antibody responses were determined at days 0, 21 and 35

282 Serum antibody responses were determined by means of hemagglut

283 nd B-lymphocyte subset analysis and antidrug antibody responses were extracted from the supplied docu

284 The highest RSV neutralizing antibody responses were in the 30 microg RSV-PreF/alum,

285 ticle-unit dose, glycoprotein Zaire-specific antibody responses were in the range reported to be asso

286 driven proliferation, isotype switching, and antibody responses were measured in B cells from heteroz

287 HIV antibody responses were measured over time in the presen

288 Cellular and antibody responses were monitored.

289 Antibody responses were observed in most participants by

290 n monkeys, vaccine-induced serum and mucosal antibody responses were readily detected, as well.

291 d 58, and non-inferior HPV 6, 11, 16, and 18 antibody responses when compared with quadrivalent HPV (

292 While all mice showed ESAT-6-specific antibody responses when infected with SL3261/surf or SL3

293 DNA/MVA vaccine by enhancing gp120 and V1/V2 antibody responses, whereas potential protection by gp12

294 nogen boosts enhanced potentially protective antibody responses, whereas the gp120 protein boosts als

295 understanding the quality of vaccine-induced antibody responses, which includes not only the neutrali

296 ion of gp120 with gp41 and to evade the host antibody response with the need to respond to CD4 bindin

297 adjuvant, are shown to provoke OspA-specific antibody responses with a strong Th1-bias (dominance of

298 ive Tier 1A isolates and weaker neutralizing antibody responses with an average titer of about 115 ag

299 nv to CD40 gave more robust T cell and serum antibody responses with broader epitope representation a

300 ves emerged, indicating costs of mounting an antibody response: younger individuals survived best whe